![Sara Nayeem](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sara Nayeem
Directeur/Membre du Conseil chez
CENTREXION THERAPEUTICS CORPORATION
Profil
Sara Nayeem currently works at Centrexion Therapeutics Corp., as Director from 2018, New England Venture Capital Association, Inc., as Director, Cydan LLC, as Director, Tiburio Therapeutics, Inc., as Director, and Enavate Sciences, as Executive Vice President-Investments from 2023.
Dr. Nayeem also formerly worked at Mersana Therapeutics, Inc., as Independent Director from 2012 to 2018, Cydan II, Inc., as Director, Biohealth Innovation, Inc., as Director, Vtesse, Inc., as Director from 2014 to 2017, NightstaRx Ltd., as Director, Therachon SAS, as Director, Imara, Inc., as Independent Director from 2016 to 2021, Xperi Corp., as Director from 2016 to 2018, Therachon AG, as Director from 2015 to 2016, Complexa, Inc., as Director, Morgan Stanley & Co. LLC, as Investment Banking Analyst, NEA Management Co. LLC, as Partner from 2015 to 2021, Merrill Lynch Global Private Equity, Inc., as Associate, Merrill Lynch & Co., Inc., as Associate from 2006 to 2009, New Enterprise Associates LLC, as Partner from 2009 to 2021, and Avoro Ventures LLC, as Partner from 2021 to 2023.
Dr. Nayeem received her undergraduate degree from Harvard University and Masters Business Admin degree and doctorate degree from Yale University.
Postes actifs de Sara Nayeem
| Sociétés | Poste | Début |
|---|---|---|
| CENTREXION THERAPEUTICS CORPORATION | Directeur/Membre du Conseil | 01/01/2018 |
Cydan LLC
 Cydan LLC Medical DistributorsDistribution Services Operates as an orphan drug accelerator that identifies and de-risks programs | Directeur/Membre du Conseil | - |
New England Venture Capital Association, Inc.
 New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services Operates trade association that encourages constructive interaction among the region's venture firms by promoting camaraderie among its members | Directeur/Membre du Conseil | - |
Tiburio Therapeutics, Inc.
 Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnological research and developmental services | Directeur/Membre du Conseil | - |
Enavate Sciences
 Enavate Sciences Financial ConglomeratesFinance Invests and supports therapeutic & enabling technology companies | Corporate Officer/Principal | 01/12/2023 |
Anciens postes connus de Sara Nayeem
| Sociétés | Poste | Fin |
|---|---|---|
Avoro Ventures LLC
 Avoro Ventures LLC Investment ManagersFinance Avoro Ventures invests in public and private companies located in the United States. The firm focuses on life sciences and biotechnology. It participates in seed, early, and late stage transactions. | Private Equity Investor | 31/10/2023 |
| IMARA | Directeur/Membre du Conseil | 15/11/2021 |
NEA Management Co. LLC
 NEA Management Co. LLC Investment ManagersFinance New Enterprise Associates seeks invests in companies located across the globe. The firm targets companies operating in the fields of technology (software & services, systems, consumer & internet, energy), healthcare (biopharms, devices, services). The firm provides financing for seed, early and growth stage capital requirements. | Private Equity Investor | 01/02/2021 |
New Enterprise Associates LLC
 New Enterprise Associates LLC Investment ManagersFinance Operates as a venture capital firm | Corporate Officer/Principal | 01/02/2021 |
| ░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Sara Nayeem
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
74
Relations au 1er degré
23
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 23 |
|---|---|
Mersana Therapeutics, Inc.
 Mersana Therapeutics, Inc. BiotechnologyHealth Technology Develops and manufactures antibody drug conjugates to improve patient outcomes in multiple oncology indications | Health Technology |
Centrexion Therapeutics Corp.
 Centrexion Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Develops therapies for chronic pain and autoimmune disease | Health Technology |
Morgan Stanley & Co. LLC
 Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NEA Management Co. LLC
NEA Management Co. LLC Investment ManagersFinance New Enterprise Associates seeks invests in companies located across the globe. The firm targets companies operating in the fields of technology (software & services, systems, consumer & internet, energy), healthcare (biopharms, devices, services). The firm provides financing for seed, early and growth stage capital requirements. | Finance |
Merrill Lynch Global Private Equity, Inc.
 Merrill Lynch Global Private Equity, Inc. Investment ManagersFinance MLGP's objective is to generate long-term capital gains, with a primary focus on control-oriented investments in equity, equity-related and similar securities with equity-like returns. Investments typically range in size from $250 million to $750 million, with the flexibility to commit to larger or smaller investments. MLGP makes investments globally, with a primary emphasis on the world's largest economies, including the US, Europe, Japan, China, India, Latin America and Australia, taking a multi-sector approach to identifying attractive investment opportunities. They target investments in high quality, established companies that are recognized brands with industry or regional leadership, defensible market positions, strong cash flow characteristics and seasoned management. They combine comprehensive regional and industry-based in-depth analyses with global approval and management processes. Their approach combines an intensive, bottom-up evaluation process including gaining a detailed understanding of a potential portfolio company's value drivers, management capabilities, cost structure, cash flow characteristics, market position and competitive advantages with a top-down analysis of the attractiveness, growth potential and underlying economics of the industry, competitive environment and exit alternatives. When making an investment, MLGPE takes a control-oriented approach and seeks to structure transactions to ensure the ability to influence critical decisions for a portfolio company, particularly as it relates to specific value-added initiatives. A key element of their transaction negotiation with partners and management centers on contractual rights and board representation that facilitate input into key decisions such as management changes, expansion plans, acquisitions, budgets, debt and equity financings and new initiatives. MLGP implements value creation initiatives such as organic growth alternatives, acquisitions and other strategic initiatives, business rationalization and operational improvements and capital structure improvements in partnership with portfolio company management. They are actively involved in significant portfolio company decisions, including those relating to potential acquisitions, expansion plans, debt and equity financings, changes in senior management and new business initiatives. | Finance |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services Operates trade association that encourages constructive interaction among the region's venture firms by promoting camaraderie among its members | Commercial Services |
Complexa, Inc.
 Complexa, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on discovering and developing therapies for the treatment inflammatory and metabolic diseases | Health Technology |
Merrill Lynch & Co., Inc.
 Merrill Lynch & Co., Inc. Investment ManagersFinance Provides wealth management, securities trading and sales, corporate finance and investment banking services | Finance |
Cydan II, Inc.
 Cydan II, Inc. Pharmaceuticals: GenericHealth Technology Develops and commercializes drugs | Health Technology |
Cydan LLC
Cydan LLC Medical DistributorsDistribution Services Operates as an orphan drug accelerator that identifies and de-risks programs | Distribution Services |
Biohealth Innovation, Inc.
 Biohealth Innovation, Inc. Financial ConglomeratesFinance Sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth | Finance |
Vtesse, Inc.
 Vtesse, Inc. BiotechnologyHealth Technology Engages in pre-clinical and clinical studies and develops drugs for patients suffering from diseases | Health Technology |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services development of therapies for retinal dystrophies | Health Services |
Therachon SAS
 Therachon SAS BiotechnologyHealth Technology Provides biotechnology services | Health Technology |
Imara, Inc.
 Imara, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes novel therapeutics for patients with sickle cell disease | Health Technology |
Xperi Corp.
 Xperi Corp. SemiconductorsElectronic Technology Manufactures semiconductors and related products | Electronic Technology |
New Enterprise Associates LLC
New Enterprise Associates LLC Investment ManagersFinance Operates as a venture capital firm | Finance |
Tiburio Therapeutics, Inc.
Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnological research and developmental services | Health Technology |
Therachon AG | |
Avoro Ventures LLC
Avoro Ventures LLC Investment ManagersFinance Avoro Ventures invests in public and private companies located in the United States. The firm focuses on life sciences and biotechnology. It participates in seed, early, and late stage transactions. | Finance |
Enavate Sciences
Enavate Sciences Financial ConglomeratesFinance Invests and supports therapeutic & enabling technology companies | Finance |
